Top

Supportive Care in Cancer

Published in:

01-09-2013 | Original Article

Testosterone replacement for fatigue in hypogonadal ambulatory males with advanced cancer: a preliminary double-blind placebo-controlled trial

Authors: E. Del Fabbro, J. M. Garcia, R. Dev, D. Hui, J. Williams, D. Engineer, J. L. Palmer, L. Schover, E. Bruera

Published in: Supportive Care in Cancer | Issue 9/2013

Abstract

Background

Uncontrolled studies show fatigue, anorexia, depression, and mortality are associated with low testosterone in men with cancer. Testosterone replacement improves quality of life and diminishes fatigue in patients with non-cancer conditions. The primary objective was to evaluate the effect of testosterone replacement on fatigue in hypogonadal males with advanced cancer, by the Functional Assessment of Chronic Illness Therapy-Fatigue subscale (FACIT-Fatigue) at day 29.

Methods

This is a randomized, double-blinded placebo-controlled trial. Outpatients with advanced cancer, bioavailable testosterone (BT) <70 ng/dL and fatigue score >3/10 on the Edmonton Symptom Assessment Scale were eligible. Intra-muscular testosterone or sesame seed oil placebo was administered every 14 days to achieve BT levels 70–270 ng/dL.

Results

Sixteen placebo and 13 testosterone-treated subjects were evaluable. No statistically significant difference was found for FACIT-fatigue scores between arms (−2 ± 12 for placebo, 4 ± 8 for testosterone, p = 0.11). Sexual Desire Inventory score (p = 0.054) and performance status (p = 0.02) improved in the testosterone group. Fatigue subscale scores were significantly better (p = 0.03) in those treated with testosterone by day 72.

Conclusions

Four weeks of intramuscular testosterone replacement in hypogonadal male patients with advanced cancer did not significantly improve quality of life. Larger studies of longer duration are warranted.

Strasser F, Palmer JL, Schover LR et al (2006) The impact of hypogonadism and autonomic dysfunction on fatigue, emotional function, and sexual desire in male patients with advanced cancer: a pilot study. Cancer 107:2949–2957CrossRef

Burney BO, Hayes TG, Smiechowska J et al (2012) Low testosterone levels and increased inflammatory markers in patients with cancer and relationship with cachexia. J Clin Endocrinol Metab 97:700–709CrossRef

Chlebowski RT, Heber D (1982) Hypogonadism in male patients with metastatic cancer prior to chemotherapy. Cancer Res 42:2495–2498PubMed

Del Fabbro E, Hui D, Nooruddin ZI et al (2010) Associations among hypogonadism, C-reactive protein, symptom burden, and survival in male cancer patients with cachexia: a preliminary report. J Pain Symptom Manag 39:1016–1024CrossRef

Rabkin JG, Wagner GJ, Rabkin R (2000) A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Arch Gen Psychiatry 57:141–147CrossRef

Patrick DL, Ferketich SL, Frame PS et al (2004) National Institutes of Health State-of-the-Science Conference Statement: Symptom management in cancer: pain, depression, and fatigue, July 15–17, 2002. National Institutes of Health State-of-the-Science Panel. J Natl Cancer Inst Monogr 32:9–16

Bhasin S, Cunningham GR, Hayes FJ et al (2006) Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 91:1995–2010CrossRef

Garcia JM, Li H, Mann D, Epner D et al (2006) Hypogonadism in male patients with cancer. Cancer 106:2583–2591CrossRef

Rajagopal A, Vassilopoulou-Sellin R, Palmer JL, Kaur G, Bruera E (2004) Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer 100:851–858CrossRef

10.

Gerl A, Muhlbayer D, Hansmann G, Mraz W, Hiddemann W (2001) The impact of chemotherapy on Leydig cell function in long term survivors of germ cell tumors. Cancer 91:1297–1303CrossRef

11.

Dev R, Del Fabbro E, Bruera E (2007) Association between megestrol acetate treatment and symptomatic adrenal insufficiency with hypogonadism in male patients with cancer. Cancer 110:1173–1177CrossRef

12.

Malkin CJ, Pugh PJ, Morris PD, Kerry KE, Jones RD, Jones TH, Channer KS (2004) Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart 90:871–878CrossRef

13.

Chiang HS, Cho SL, Lin YC, Hwang TI (2009) Testosterone gel monotherapy improves sexual function of hypogonadal men mainly through restoring erection: evaluation by IIEF score. Urology 73:762–766CrossRef

14.

Cherrier MM, Asthana S, Plymate S, Baker L, Matsumoto AM, Peskind E, Raskind MA, Brodkin K, Bremner W, Petrova A, LaTendresse S, Craft S (2001) Testosterone supplementation improves spatial and verbal memory in healthy older men. Neurology 57:80–88CrossRef

15.

Bhasin S, Storer TW, Javanbakht M, Berman N, Yarasheski KE, Phillips J, Dike M, Sinha-Hikim I, Shen R, Hays RD, Beall G (2000) Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. JAMA 283:763–770CrossRef

16.

Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D, Perry HM (2000) Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 49:1239–1242CrossRef

17.

Bruera E, Kuehn N, Miller MJ et al (1991) The Edmonton Symptom Assessment System (ESAS). J Palliat Care 7:6–9CrossRef

18.

Chang VT, Hwang SS, Feuerman M (2000) Validation of the Edmonton Symptom Assessment Scale. Cancer 88:2164–2171CrossRef

19.

Cella D, Tulsky DS, Gray G et al (1993) The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 11:570–579CrossRef

20.

Ribaudo JM, Cella D, Hahn EA, Lloyd SR, Tchekmedyian NS et al (2000) Re-validation and shortening of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) questionnaire. Qual Life Res 9:1137–1146CrossRef

21.

Johnston M, Pollard B, Hennessey P (2000) Construct validation of the hospital anxiety and depression scale with clinical populations. J Psychosomatic Res 48:579–584CrossRef

22.

Spector IP, Carey MP, Steinberg L (1996) The Sexual Desire Inventory: development, factor structure, and evidence of reliability. J Sex Marital Ther 22:175–190CrossRef

23.

Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC et al (1992) for The Measurement Committee of the American Urological Association, The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 148:1549–1557CrossRef

24.

American Thoracic Society (2002) ATS Statement: Guidelines for the Six-Minute Walk Test. Am J Respir Crit Care Med 166:111–117CrossRef

25.

Sousa N, Sampaio J (2005) Effects of progressive strength training on the performance of the Functional Reach Test and the Timed Get-Up-and-Go Test. Am J Hum Biol 17:746–751CrossRef

26.

Wheeler MJ (1995) The determination of bioavailable testosterone. Ann Clin Biochem 32:345–357CrossRef

27.

Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J ClinOncol 5:649–655CrossRef

28.

Lai JS, Beaumont JL, Ogale S, Brunetta P, Cella D (2011) Validation of the functional assessment of chronic illness therapy-fatigue scale in patients with moderately to severely active systemic lupus erythematosus, participating in a clinical trial. J Rheumatol 38:672–679CrossRef

29.

Cella D, Hahn EA, Dineen K (2002) Meaningful change in cancerspecific quality of life scores: differences between improvement and worsening. Qual Life Res 11:207–221CrossRef

30.

Yost KJ, Sorensen MV, Hahn EA, Glendenning GA, Gnanasakthy A, Cella D (2005) Using multiple anchor- and distribution-based estimates to evaluate clinically meaningful change on the Functional Assessment of Cancer Therapy-Biologic Response Modifiers (FACT-BRM) instrument. Value Health 8:117–127CrossRef

31.

Cella D, Eton DT, Lai JS et al (2002) Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment ofCancer Therapy (FACT) Anemia and Fatigue scales. J PainSymptom Manage 24:547–561CrossRef

32.

Lindau ST, Gavrilova N (2010) Sex, health, and years of sexually active life gained due to good health: evidence from two US population based cross sectional surveys of ageing. BMJ 9:340–c810

33.

Garcia JM, Li H, Mann D, Epner D, Hayes TG, Marcelli M, Cunningham GR (2006) Hypogonadism in male patients with cancer. Cancer 106:2583–2591CrossRef

34.

Shafqat A, Einhorn LH, Hanna N, Sledge GW, Hanna A, Juliar BE, Monahan P, Bhatia S (2005) Screening studies for fatigue and laboratory correlates in cancer patients undergoing treatment. Ann Oncol 16:1545–1550CrossRef

35.

Coviello AD, Kaplan B, Lakshman KM, Chen T, Singh AB, Bhasin S (2008) Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab 93:914–919CrossRef

36.

Munch TN, Zhang T, Willey J, Palmer JL, Bruera E (2005) The association between anemia and fatigue in patients with advanced cancer receiving palliative care. J Palliat Med 8:1144–1149CrossRef

37.

Minton O, Strasser F, Radbruch L, Stone P (2012) Identification of factors associated with fatigue in advanced cancer: a subset analysis of the European palliative care research collaborative computerized symptom assessment data set. J Pain Symptom Manage 43(2):226–235CrossRef

38.

Mercadante S, Ferrera P, Villari P, David F, Giarratano A, Riina S (2009) Effects of red blood cell transfusion on anemia-related symptoms in patients with cancer. J Palliat Med 12:60–63CrossRef

39.

Trutschnigg B, Kilgour RD, Reinglas J, Rosenthall L, Hornby L, Morais JA, Vigano A (2008) Precision and reliability of strength (Jamar vs. Biodex handgrip) and body composition (dual-energy X-ray absorptiometry vs. bioimpedance analysis) measurements in advanced cancer patients. Appl Physiol Nutr Metab 33:1232–1239CrossRef

40.

MacDonald AJ, Greig CA, Baracos V (2011) The advantages and limitations of cross-sectional body composition analysis. Curr Opin Support Palliat Care 5:342–349CrossRef

41.

Eggertson L (2011) Brouhaha erupts over testosterone-testing advertising campaign. CMAJ 183:1161–1162CrossRef

42.

Marks LS, Mazer NA, Mostaghel E et al (2006) Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA 296:2351–2361CrossRef

43.

Rhoden EL, Morgentaler A (2003) Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J Urol 170:2348–2351CrossRef

Title: Testosterone replacement for fatigue in hypogonadal ambulatory males with advanced cancer: a preliminary double-blind placebo-controlled trial
Authors: E. Del Fabbro
J. M. Garcia
R. Dev
D. Hui
J. Williams
D. Engineer
J. L. Palmer
L. Schover
E. Bruera
Publication date: 01-09-2013
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 9/2013
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-013-1832-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 9/2013

A prospective study of characteristics and outcomes of bacteremia in patients with solid organ or hematologic malignancies

Unmet needs in immigrant cancer survivors: a cross-sectional population-based study

Predictors of response to palliative care intervention for chronic nausea in advanced cancer outpatients

Assessing information and service needs of young adults with cancer at a single institution: the importance of information on cancer diagnosis, fertility preservation, diet, and exercise

Distress among young adult cancer survivors: a cohort study

Factors associated with depressive symptoms in cancer family caregivers of patients receiving chemotherapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer